pentobarbital will lessen the extent or effect of mestranol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will decrease the extent or influence of ondansetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. No dosage adjustment for ondansetron is usually recommended for sufferers on these drugs.
pentobarbital will minimize the extent or influence of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will reduce the level or effect of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will lessen the extent or effect of tacrolimus by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
This drug may perhaps raise the metabolism of estradiol when administered concurrently; sufferers on oral contraceptives have grown to be pregnant when concurrently handled with antiepileptic drugs; suggest an alternate contraceptive technique to Gals having this drug
pentobarbital will lower the extent or outcome of terbinafine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will lessen the extent or more info influence of finasteride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Not known.
pentobarbital will lessen the extent or outcome of tamoxifen by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
If the buprenorphine dose is inadequate plus the CYP3A4 inducer can't be minimized or discontinued, transition the affected person back again to the buprenorphine formulation that permits dose changes.
pentobarbital decreases levels of toremifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. CYP3A4 inducers maximize price of toremifene metabolism, decreasing the constant-state concentration in serum.
pentobarbital decreases effects of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of CYP3A4 inducers may possibly minimize sufentanil ranges and efficacy, potentially precipitating withdrawal syndrome in clients which have developed Actual physical dependence to sufentanil. Discontinuation of concomitantly used CYP3A4 inducers may possibly enhance sufentanil plasma focus.
Observe Intently (one)pentobarbital will minimize the level or result of benzhydrocodone/acetaminophen by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Caution when discontinuing CYP3A4 inducers which have been coadministered with benzhydrocodone (prodrug of hydrocodone); plasma concentrations of hydrocodone might enhance and may result in most likely lethal respiratory despair.
pentobarbital will decrease the extent or outcome of norgestrel by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Intently. Reasonable CYP3A4 inducers may well reduce progestin focus; consider utilization of supplemental barrier techniques